These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 14991904)

  • 1. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas.
    Pan CC; Chen PC; Chiang H
    J Pathol; 2004 Mar; 202(3):375-81. PubMed ID: 14991904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of gene mutations in KIT-positive thymic epithelial tumors.
    Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
    Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
    Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
    Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of proteasome subunit β5t in thymic epithelial tumors.
    Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
    Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma.
    Pan CC; Chen PC; Chiang H
    Am J Clin Pathol; 2004 Jun; 121(6):878-83. PubMed ID: 15198361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours.
    Andreadis D; Epivatianos A; Poulopoulos A; Nomikos A; Papazoglou G; Antoniades D; Barbatis C
    Oral Oncol; 2006 Jan; 42(1):57-65. PubMed ID: 16140564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
    Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
    Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
    Huo L; Sugimura J; Tretiakova MS; Patton KT; Gupta R; Popov B; Laskin WB; Yeldandi A; Teh BT; Yang XJ
    Hum Pathol; 2005 Mar; 36(3):262-8. PubMed ID: 15791570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma.
    Holst VA; Marshall CE; Moskaluk CA; Frierson HF
    Mod Pathol; 1999 Oct; 12(10):956-60. PubMed ID: 10530560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase receptor expression in thymomas.
    Henley JD; Cummings OW; Loehrer PJ
    J Cancer Res Clin Oncol; 2004 Apr; 130(4):222-4. PubMed ID: 14762710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
    Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
    Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma.
    Dorfman DM; Shahsafaei A; Miyauchi A
    Mod Pathol; 1998 Oct; 11(10):989-94. PubMed ID: 9796728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma.
    Biermann K; Göke F; Nettersheim D; Eckert D; Zhou H; Kahl P; Gashaw I; Schorle H; Büttner R
    J Pathol; 2007 Nov; 213(3):311-8. PubMed ID: 17768701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of gene mutations in KIT-positive carcinoma showing thymus-like elements of the thyroid.
    Pan Y; Zhao X; Yang J; Deng J; Zhan Z; Luo Y; Li Q; Guo Y; Zhai Q; Sun B
    Hum Pathol; 2012 Mar; 43(3):350-5. PubMed ID: 21835435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymic carcinoma: is it a separate entity? From molecular to clinical evidence.
    Marx A; Rieker R; Toker A; Länger F; Ströbel P
    Thorac Surg Clin; 2011 Feb; 21(1):25-31. v-vi. PubMed ID: 21070984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    J Surg Oncol; 2009 Jun; 99(7):433-8. PubMed ID: 19347882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
    Chan JK; Tsang WY; Seneviratne S; Pau MY
    Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma.
    Mino M; Pilch BZ; Faquin WC
    Mod Pathol; 2003 Dec; 16(12):1224-31. PubMed ID: 14681323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas.
    Zigeuner R; Ratschek M; Langner C
    BJU Int; 2005 Feb; 95(3):315-8. PubMed ID: 15679785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation ratio of MMP-2 and expression of MT1-MMP are correlated in thymic epithelial tumours.
    Wang Y; Xu HT; Ueda Y; Shimasaki M; Wang EH
    Pathology; 2007 Oct; 39(5):486-90. PubMed ID: 17886098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.